Kevin Sheth, MD, FANA
Yale School of Medicine
Dr. Kevin Sheth is the Vice Chair for Clinical & Translational Research in Neurology & Neurosurgery and a founding Director of the Yale Center for Brain & Mind Health. Dr. Sheth is recognized for his leadership in prevention, acute treatment, and recovery stroke research. He has led and developed highly innovative programs in drug development, translation, and medical devices. His team at Yale has served as a national model for academic neurology units. Dr. Sheth has served as PI or co-PI for eight multicenter clinical trials in stroke, as well as chair for clinical endpoint and data safety monitoring committees for several pivotal studies. He is a winner of the prestigious Robert Siekert Award from the American Heart Association (AHA), the Derek Denny Brown Award from the American Neurological Association and an elected member of the American Society for Clinical Investigation (ASCI). He has mentored dozens of investigators and received the Stroke Mentorship Award from the American Heart Association (AHA). His research has been funded by the NIH, American Academy of Neurology, AHA, and the US Army. Dr. Sheth is the author of over 300 publications, and he has served on study sections for the NIH, AHA, FDA and NASA. He is an Associate Editor at Stroke and a former member of the American Neurological Association and Neurocritical Care Society Board of Directors. His work has been showcased in The Washington Post, Wall Street Journal, NPR, CNN, BBC and Scientific American. Finally, Dr. Sheth has formed exciting partnerships with entrepreneurs, pharmaceutical companies, and medical device start-ups to bring forward highly innovative solutions. He holds several patents and is a co-founder for early-stage companies. These efforts have resulted in extensive knowledge of FDA pathways, development of phase I-III drug programs, and implementation of new technology into the clinical workspace. A foremost example is the successful translation of glyburide from laboratory to multiple phase II studies. Ultimately, this asset was acquired from Remedy Pharmaceuticals by Biogen at the phase III stage. Similarly, he led the deployment to identify and acquire proof of concept data leading to FDA clearance for the world’s first clinically relevant portable MRI system. Overall, the principal theme of his efforts are towards collaboration and an improved understanding of neurological disease.